Chronic Total Occlusion Market is expected to reach US$ 4.22 Billion by 2031

Guide Wires Segment to Bolster Chronic Total Occlusion Market Growth During 2025–2031

According to our new research study on "Chronic Total Occlusion Market Forecast to 2031 – Global Analysis – by Equipment and End User," the market was valued at US$ 2.44 billion in 2024 and is projected to reach US$ 4.22 billion by 2031; it is anticipated to record a CAGR of 8.2% from 2025 to 2031.

The report emphasizes the chronic total occlusion market trends, along with drivers and deterrents affecting the market growth. The increasing aging population and the rising prevalence of cardiovascular diseases are contributing to the growing chronic total occlusion market size. However, the high cost of occlusion devices hampers the market growth. Further, technological advancements in CTO devices is expected to emerge as a new market trend in the coming years.

Chronic Total Occlusion Market Share, by Region, 2024 (%)

Source: The Insight Partners Analysis

Increasing Aging Population Bolsters Chronic Total Occlusion Market Growth

The rising geriatric population is a key driver for the chronic total occlusion (CTO) market. As the world population grows older, cardiovascular diseases become more common.

According to the World Health Organization (WHO), by 2030, one in six people worldwide will be 60 years old or older. This number is projected to rise from 1 billion in 2020 to 1.4 billion in 2030 and 2.1 billion by 2050. The number of persons aged 80 or older is expected to triple between 2020 and 2050 to reach 426 million. WHO also stated that by 2050, 80% of older people will be living in low- and middle-income countries. In addition, as per the Population Reference Bureau, Asia and Europe have the oldest populations, including people aged 65 or older. With 28% of the geriatric population, Japan is leading worldwide, followed by Italy at 23%. Finland, Portugal, and Greece are among the top five countries with ~22% of the geriatric population.

Cardiovascular diseases, and more specifically heart attacks and strokes, happen more in older adults, especially those who are 60 and above. This is because of certain issues in the heart and blood vessels like build up in the vessels and reduced flexibility of blood vessels. The increasing number of aged people across the globe is the reason behind the increasing demand for treatments that are effective yet minimally invasive, such as percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Minimally invasive treatments have lower risk and faster recovery, and thus there is increasing need for such treatments especially for older adults for secondary and tertiary surgical procedures. This trend is also visible in the US, Japan, and Europe that have elderly populations.

Market players such as Boston Scientific, Abbott Laboratories, and Medtronic are also more inclined to develop sophisticated CTO devices specifically designed for the aging population. These devices make treatments available, effective, and safe for this vulnerable group.      

Chronic Total Occlusion Market Report Scope:

The chronic total occlusion market analysis has been carried out by considering the following segments: equipment, end user, and geography.

Based on equipment, the chronic total occlusion market is segmented into guide wires, micro catheters, crossing devices, re-entry devices, and others. The guide wires segment held the largest chronic total occlusion market share in 2024. A key element of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) procedures, guidewires enable medical professionals to navigate through complex, blocked coronary arteries, enabling life-saving treatments such as stent implantation, balloon angioplasty, and other therapeutic interventions. Guidewires for chronic total occlusion (CTO) interventions are tailored to navigate the complex structure of total occlusions. In addition to ease of use and precision, proprietary guidewires integrate features such as advanced torque control, flexibility, and hydrophilic coatings. In addition, participants of the guidewire market are exercising a range of inorganic and organic growth techniques. Below are some examples. 

• In February 2022, The US Food and Drug Administration (FDA) has approved Teleflex Incorporated's expanded indications for its coronary guidewires and specialty catheters, particularly for use in chronic total occlusion percutaneous coronary interventions (CTO PCI).
• In June 2024, The Intravascular Piezoelectric Guidewire System from MicroPort RotaPace was approved by the NMPA to be included in the special review processes for novel medical devices. A group from Zhongshan Hospital at Fudan University, led by Academician Junbo Ge, co-developed this system.
• In April 2020, Nitiloop Ltd. received FDA 510(k) clearance for its NovaCross chronic total occlusion (CTO) microcatheter. Nitiloop is based in Israel.

As CTO procedures become more advanced and prevalent, the demand for specialized guidewires continues to grow. The aforementioned advancements and FDA approvals underscore the continuous progress in the guidewire industry, which is driving the success of CTO PCI procedures. These guidewires are essential for increasing the effectiveness of CTO interventions, reducing operation time, and ultimately improving patient outcomes because they provide increased flexibility, improved control, and better maneuverability.

In terms of end user, the chronic total occlusion market is categorized into hospitals, ambulatory care centers, and others. The hospitals segment dominated the market in 2024. Hospitals are pivotal in driving the growth of the chronic total occlusion (CTO) market. Hospitals are the primary healthcare providers for cardiovascular conditions, they are increasingly treating coronary artery blockages with state-of-the-art CTO devices. By providing patients with a less invasive option than traditional surgery, these devices—which include guidewires, catheters, balloons, and stents—have become essential in raising the success rates of percutaneous coronary intervention (PCI) procedures.

Because of the growing prevalence of coronary artery disease and the growing demand for minimally invasive treatments, hospitals are integrating cutting-edge CTO devices into their cardiac care offerings. These tools are particularly useful when dealing with complex CTO cases, where it can be challenging to get through total occlusions and restore blood flow. By investing in these state-of-the-art technologies, hospitals can improve procedural outcomes, reduce complications, and expedite recovery.

News regarding the adoption of CTO devices by hospitals:

• Following the lead of their cardiac specialties, The Cleveland Clinic integrates the techniques of CTO PCI in treating complicated coronary blockages. The use of advanced CTO devices including specialized guidewires and balloons remarkably increases the success of their CTO procedures. 
• Integrating new CTO device technologies has not only increased the success rate of JOHNS Hopkins Hospital’s CTO PCI but has also elevated patient outcomes as the devices enabled the treatment of difficult cases. 
• With the newest CTO devices in use, their SN Santa Creu Hospital continues to improve their CTO procedures and with it, enhance patient recovery and satisfaction. 

The use of CTO devices in hospitals is creating a new outlook of treatment of chronic total occlusion in interventional cardiology, thereby creating a new market for these devices. As hospitals continue to integrate advanced CTO devices, the demand for these technologies will propel the CTO devices market growth for this segment.

Chronic Total Occlusion Market Analysis: Based on Geography

The geographic scope of the chronic total occlusion market includes the assessment of the market performance in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), South and Central America (Brazil, Argentina, and Rest of South and Central America), and the Middle East and Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East and Africa).    

US Census Bureau, World Health Organization (WHO), British Heart Foundation, French National Institute for Demographic Studies, National Institute of Statistics (NIS), National Library of Medicine, National Crime Records Bureau (NCRB), and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the chronic total occlusion market report.    

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com